DelveInsight’s, “Myelodysplastic Syndrome Pipeline Insight 2023” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Myelodysplastic Syndrome Pipeline Report

• DelveInsight’s Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Myelodysplastic Syndrome treatment.
• The leading companies working in the Myelodysplastic Syndrome Market include Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
• Promising Myelodysplastic Syndrome Pipeline Therapies in the various stages of development include Venetoclax, Azacitidine, Luspatercept, Epoetin alfa, FG-4592, Lenalidomide 5 mg, and others.
• December 2023: Celgene announced a study of Phase 3 clinical trials for Luspatercept and Epoetin Alfa. The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at least 1.5 g/dL in participants with anemia due to revised international prognostic scoring system (IPSS-R) very low, low, or intermediate risk myelodysplastic syndromes (MDS) who require RBC transfusions and have never been exposed to erythropoiesis stimulating agent (ESA).
• December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Luspatercept and Epoetin Alfa. The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
• December 2023: Celgene announced a study of Phase 1 clinical trials for CC-91633. Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The Dose Escalation part (Part A) of the study will enroll participants with R/R AML and R/R HR-MDS and will evaluate the safety and tolerability of escalating doses of CC-91633 (BMS-986397), administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.

 

Request a sample and discover the recent advances in Myelodysplastic Syndrome Treatment Drugs @ Myelodysplastic Syndrome Pipeline Outlook Report

 

In the Myelodysplastic Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Myelodysplastic Syndrome Overview

Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. Some patients with MDS may have a transformation into acute myeloid leukemia (AML). MDS is usually diagnosed in older patients over the age of 65. Clinical manifestations include a decrease in the number of red blood cells (RBC), platelets, and white blood cells (WBC). The disease course is variable.

 

Find out more about Myelodysplastic Syndrome Treatment Landscape @ Drugs for Myelodysplastic Syndrome Treatment

 

Myelodysplastic Syndrome Emerging Drugs Profile

• MBG453: Novartis
• Tamibarotene: Syros Pharmaceuticals
• CA-4948: Curis
• RVU120: Ryvu Therapeutics

 

Myelodysplastic Syndrome Pipeline Therapeutics Assessment

There are approx. 120+ key companies which are developing the therapies for Myelodysplastic Syndrome. The Myelodysplastic Syndrome companies which have their Myelodysplastic Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Novartis.

 

DelveInsight’s Myelodysplastic Syndrome Pipeline Report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Myelodysplastic Syndrome Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Learn more about the emerging Myelodysplastic Syndrome Pipeline Therapies @ Myelodysplastic Syndrome Clinical Trials Assessment

 

Scope of the Myelodysplastic Syndrome Pipeline Report

• Coverage- Global
• Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Myelodysplastic Syndrome Companies- Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
• Myelodysplastic Syndrome Pipeline Therapies- Venetoclax, Azacitidine, Luspatercept, Epoetin alfa, FG-4592, Lenalidomide 5 mg, and others.

 

Dive deep into rich insights for new drugs for Myelodysplastic Syndrome treatment, Visit @ Myelodysplastic Syndrome Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Myelodysplastic Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myelodysplastic Syndrome– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. MBG453: Novartis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CA-4948: Curis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RVU120: Ryvu Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Myelodysplastic Syndrome Key Companies
21. Myelodysplastic Syndrome Key Products
22. Myelodysplastic Syndrome- Unmet Needs
23. Myelodysplastic Syndrome- Market Drivers and Barriers
24. Myelodysplastic Syndrome- Future Perspectives and Conclusion
25. Myelodysplastic Syndrome Analyst Views
26. Myelodysplastic Syndrome Key Companies
27. Appendix

 

For further information on the Myelodysplastic Syndrome Pipeline Therapeutics, reach out @ Myelodysplastic Syndrome Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market